IL-17、干扰素-γ在红斑狼疮患者体内的表达及地塞米松对其的抑制作用

目的研究系统性红斑狼疮（SLE）患者血浆及外周血单个核细胞（PBMCs）中IL-17、IFN-γ的表达水平，探讨地塞米松对PBMC分泌IL-17和IFN-γ的影响。方法采用双抗体夹心酶联免疫吸附法（ELISA）测定SLE患者和健康对照者血浆及PBMCs培养上清液中IL-17、IFN-γ的表达水平。结果SLE患者组血浆IL-17、IFN-γ含量均高于健康对照组（t=d．96，P〈0．001；t=2．43，P〈0．05），SLE活动组患者血浆IL-17水平明显高于非活动组（t=g．52，P〈0．005）；血浆IL-17水平与SLE疾病活动性指数（SLEDAI）、抗dsDNA抗体滴度呈正相关（r=0．681，0．492），与补体C3、C4水平呈负相关（r=-0．529，-0．534）。无佛波酯（PMA）刺激条件下，SLE患者PBMCs培养上清液中细胞因子水平与对照组均无显著差异（t=0．06，P〉0．05）．力口人PMA刺激后，SLE患者PBMCs分泌IL—17的水平显著高于正常对照组（t=2．48，P〈0．05）；地塞米松可明显抑制PMA刺激后的PBMCs分泌IL-17和IFN-γ水平（t=3．72，3．34，P〈0．01），且地塞米松对PBMCs分泌IL-17的抑制率更高。结论SLE患者体内细胞因子的表达水平存在明显异常，IL-17表达水平显著增高，且与疾病活动性有明显关联，地塞米松可明显抑制IL-17的表达，提示IL—17可能是治疗SLE的一个潜在的新靶点。

Expression of IL-17 and IFN-γ in peripheral blood of patients with systemic lupus erythematosus and inhibition of dexamethasone on the secretion of cytokines

Objective To determine the levels of interleukin (IL)-17 and interferon (IFN)-γ in the plasma and in the peripheral blood mononuclear cell (PBMCS) of patients with systemic lupus erythematosus (SLE) and to investigate the effect of dexamethasone(DEX) on the secretion of IL-17 and IFN-γin PBMCs.Methods Concentrations of IL-17 and IFN-γ in plasma and in the supernatants of PBMCs which were cultured for 24 hours were measured by enzyme linked immunosorbent assay (ELISA). Results The plasma concentrations of IL-17 and IFN-γwere elevated in SLE patients as compared to the normal controls(t =4. 96,p ＜0. 001;t=2.43,p＜0.05;t=4.52,p＜0.005).The levels of plasma IL-17 showed a positive correlation with SLEDAI and the titers of anti-dsDNA antibody on the contrary(r = 0. 681,0. 492), the levels of plasma IL-17 showed a negative correlation with the levels of complement C3/C4 (r = - 0. 529, - 0. 534). No significant differences were observed between patients and controls for the spontaneous production of IL-17 and IFN-γby PBMC. Compared with normal controls after the stimulation of PMA,the level of IL-17 was significantly elevated in the supernatants of PBMCs(t = 2. 48, P ＜ 0. 05). DEX could significantly decrease the production of IL-17 and IFN-γ by PBMC (t = 3.72,3.34, P ＜0. 01). DEX showed more powerful potential of inhibiting the secretion of IL-17 by PBMC. Conclusion The expression of cytokines is obviously abnormal in SLE patients. Plasma IL-17 in SLE patients are significantly elevated and DEX can inhibit the production of IL-17. The close relationship between IL-17 and disease activity suggests that IL-17 may be a new potential target in the treatment of SLE.